Incyte Corporation (NasdaqGS:INCY) entered into stock purchase agreement to acquire 2.92% Syndax Pharmaceuticals, Inc. (NasdaqGS : SNDX) for $35 million on September 24, 2021. Incyte has agreed to purchase 1,421,523 shares (the “ Shares ”) of common stock, par value $0.0001 per share, of the Company (the “ Common Stock ”) for an aggregate purchase price of $35 million, or $24.62 per share. Under the Purchase Agreement, Incyte has agreed, subject to limited exceptions, not to sell or otherwise transfer any of the Shares for a six-month period. Closing of the purchase of the Shares is expected to occur concurrently with the effectiveness of the Collaboration Agreement following early termination or expiration of the HSR Waiting Period and is subject to customary conditions, as well as the continued effectiveness of the Collaboration Agreement.